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Abstract
Background: Plasma and cerebrospinal fluid levels of neurofilament light (NfL), a marker of axonal degeneration,
have previously been reported to be raised in patients with clinically diagnosed Alzheimer’s disease (AD). Activated
microglia, an intrinsic inflammatory response to brain lesions, are also known to be present in a majority of Alzheimer
or mild cognitive impaired (MCI) subjects with raised β-amyloid load on their positron emission tomography (PET)
imaging. It is now considered that the earliest phase of inflammation may be protective to the brain, removing
amyloid plaques and remodelling synapses. Our aim was to determine whether the cortical inflammation/microglial
activation load, measured with the translocator protein marker 11C-PK11195 PET, was correlated with plasma NfL levels
in prodromal and early Alzheimer subjects.
Methods: Twenty-seven MCI or early AD cases with raised cortical β-amyloid load had 11C-(R)-PK11195 PET, structural
and diffusion magnetic resonance imaging, and levels of their plasma NfL measured. Correlation analyses were
performed using surface-based cortical statistics.
Results: Statistical maps localised areas in MCI cases where levels of brain inflammation correlated inversely with
plasma NfL levels. These areas were localised in the frontal, parietal, precuneus, occipital, and sensorimotor cortices.
Brain inflammation correlated negatively with mean diffusivity (MD) of water with regions overlapping.
Conclusion: We conclude that an inverse correlation between levels of inflammation in cortical areas and plasma NfL
levels indicates that microglial activation may initially be protective to axons in AD. This is supported by the finding
of an inverse association between cortical water diffusivity and microglial activation in the same regions. Our findings
suggest a rationale for stimulating microglial activity in early and prodromal Alzheimer cases—possibly using
immunotherapy. Plasma NfL levels could be used as a measure of the protective efficacy of immune stimulation and
for monitoring efficacy of putative neuroprotective agents.
Keywords: Neurofilament light, Microglia, Inflammation, PET, PK11195, MCI, Alzheimer
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: peter.parbo@clin.au.dk
†Peter Parbo and Lasse Stensvig Madsen contributed equally to this work.
†Peter Parbo and Lasse Stensvig Madsen Indicates joint first authorship
1Department of Nuclear Medicine and PET Centre, Aarhus University Hospital,
Aarhus, Denmark
2Department of Clinical Physiology, Viborg Regional Hospital, Viborg,
Denmark
Full list of author information is available at the end of the article
Parbo et al. Alzheimer's Research & Therapy            (2020) 12:3 
https://doi.org/10.1186/s13195-019-0574-0
Background
Neurofilaments are found in the cytoplasm of neurons
and act to transport nutrients and other molecules along
axons. The subunit proteins constituting neurofilaments
include neurofilament light (NfL), medium and heavy (L,
M and H) proteins based on their molecular weight [1].
The neurofilaments control axonal diameter, and it has
been reported that cerebrospinal fluid (CSF) levels of
NfL provide a non-specific marker of axonal degener-
ation. Patients with amyotrophic lateral sclerosis where
pyramidal tract involvement is present show greatly
raised CSF NfL levels, while those with only peripheral
motor neuron disease (progressive muscular atrophy)
show smaller elevations [2, 3]. Multiple sclerosis cases in
the chronic progressive phase of their disease also show
raised CSF NfL, but those who have early relapsing re-
mitting disease show only modest elevations [4]. Raised
levels of CSF NfL have also been reported in Alzheimer’s
disease (AD) and Huntington’s disease [2, 5, 6]. No rela-
tionship was found between cognitive status and CSF
NfL levels in AD patients, though disability of Hunting-
ton’s disease cases, when rated with the UHDRS, corre-
lated with CSF NfL levels [6].
More recently, an ultrasensitive digital array for
enzyme-linked immunosorbent assay (ELISA) of pro-
teins including NfL has been developed [7], which allows
reliable detection of single molecules of NfL in plasma
or serum. NfL plasma levels were found to correlate
strongly with those measured in CSF. A large number of
studies have now shown that blood NfL is a robust bio-
marker of neuronal injury, irrespective of the cause [8].
In the context of AD, serum NfL has been found to
mark the onset of neurodegeneration in subjects at risk
for familial disease [9]. A recent study found increased
plasma NfL in AD patients compared to nondemented
controls [10]. A larger study involving the Alzheimer’s
Disease Neuroimaging Initiative (ADNI-1) cohort re-
ported raised plasma NfL in sporadic mild cognitive
impairment (MCI) and Alzheimer cases [11]. The
plasma NfL levels correlated with reduced CSF β-
amyloid 1–42 and raised CSF tau in the MCI cohort. At
baseline, high plasma NfL levels in the MCI and AD co-
hort were associated with worse Mini-Mental State
Examination (MMSE) and ADAS-COG 11 scores and
subjects had larger ventricular and smaller hippocampal
volumes and thinner cortices.
Microglia are part of the intrinsic immune defence of
the brain but normally exist in a resting state monitoring
the local constituents of brain extracellular fluid [12]. In
AD, there is abnormal formation of extracellular plaques
of β-amyloid protein fibrils and intraneuronal tangles of
hyperphosphorylated tau. This characteristic pathology
of AD is associated with an inflammatory response
which involves activated microglia surrounding plaques
and degenerating neurons [13]. Activated, but not rest-
ing, microglia express the translocator protein (TSPO)
on the outer membranes of their mitochondria [14].
11C-PK11195 positron emission tomography (PET) is an
in vivo marker of the TSPO expressed by activated
microglia. Recently, we reported that 80% of β-amyloid-
positive MCI cases showed associated active inflamma-
tion and raised TSPO [15]. However, whether the
inflammation was playing a protective or cidal role in
the disease was unclear. It has been reported in estab-
lished AD that levels of temporoparietal cortical micro-
glial activation correlate inversely with cognitive ratings
on the MMSE [16]. This suggests that the microglial
phenotype may be toxic in these subjects. However,
microglia are known to also express protective pheno-
types releasing growth factors, clearing amyloid fibrils,
and remodelling damaged synapses. Here, we report the
presence of an inverse association of plasma NfL levels,
acquired from cases with either prodromal (β-amyloid-
positive MCI) or early clinical β-amyloid-positive AD,
with their levels of cortical microglial activation mea-
sured with 11C-(R)-PK11195 PET [17]. These findings
are corroborated by measurements of atrophy and




Subjects with MCI and clinical AD were recruited from
memory clinics and by advertisement as part of an
ongoing longitudinal PET study and were assessed as
previously described [15]. In this report, we included
amyloid-positive MCI/AD subjects who had measures of
plasma NfL, an 11C-PK11195 PET scan, and whole-brain
MRI with structural and diffusion-weighted imaging
(DWI). The MCI subjects fulfilled the Petersen clinical
criteria while the AD patients were diagnosed by demen-
tia specialists using ICD-10 criteria. All subjects were
assessed with MMSE and Clinical Dementia Rating
(CDR). The project was approved by the regional ethics
committee and all subjects gave their written informed
consent.
Plasma NfL levels
Plasma NfL concentrations were measured using an
ultrasensitive in house ‘single molecule array’ (SIMOA)
ELISA assay, as previously described in detail [7]. The
measurements were performed by a board-certified la-
boratory technician using a single batch of reagents.
Brain imaging
MRI was performed on a Skyra 3 Tesla system (Siemens,
Erlangen, Germany). An MP2RAGE (Magnetization
Prepared Rapid Gradient-Echo with two gradient echo
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images) sequence was used for co-registration of MRI
with PET, normalisation into standard space, generation
of grey matter (GM) masks, and measurements of
cortical thickness. DWI was obtained using a fast,
clinically practical, diffusion kurtosis imaging sequence
[18, 19]. Acquisitions included one b = 0 image, three
b = 1000 s/mm2, and nine b = 2500 s/mm2, all acquired
with 2.3-mm isotropic voxels, FOV = 220 × 220mm2 in
38 slices, TR = 12.4 s, TE = 0.107 s, and TI = 2.1 s. Mean
diffusivity (MD) was calculated from the DWI sequence.
MD is an imaging biomarker of early axonal degenera-
tive changes in AD [20].
Subjects were scanned using a High Resolution
Research Tomograph (ECAT HRRT; CTI/Siemens,
Knoxville, TN) as previously described [15, 21]. A mean
392MBq dose of 11C-(R)-(1-[2-chlorophenyl]-N-methyl-
N-[1-methyl-propyl]-3-isoquinolinecarboxamide) (abbre-
viated PK11195) was injected intravenously. The total
dynamic scan time was 60.5 min (list mode 3D
acquisition).
PET images were reconstructed with a 3D-OSEM
(ordered subset expectation maximum) with 10 itera-
tions and 16 subsets. Point-spread function (PSF) recon-
struction was applied to minimise partial volume effects,
improve image quality, contrast and quantitative accur-
acy, and achieve a reconstructed resolution of 2.5 mm.
Images were not partial volume corrected.
Image analyses using cortical surface maps
Parametric maps of binding potential (BPND) were
generated at a voxel level from the dynamic 11C-(R)-
PK11195 PET images using the Simplified Reference
Tissue Model (SRTM) [22] implemented in Matlab. As
all anatomical regions in the brain can potentially show
specific PK11195 binding in Alzheimer’s disease due to
local pathology or downstream disconnection, a
Supervised Cluster Analysis with 6 classes [23] (SVCA6)
was used to localise a distributed cluster of voxels from
the dynamic images of each MCI/AD case, which
provided a reference tissue input function representing
normal GM kinetics.
Surface-based cortical statistics were used to perform
the analyses. For each subject, the cortical surface was
extracted from the individual MP2RAGE image using
Fast Accurate Cortex Extraction (FACE) [24]. To map
the PK11195 PET and DWI signal onto the surface, indi-
vidual cortical surfaces were transformed into the PET/
DWI native space, respectively, using a rigid body co-
registration with the MP2RAGE image. The signal was
then interpolated and mapped to the surface approxi-
mating the middle cortical layer, in order to minimise
the influence of partial volume effects. Before mapping
the PK11195 signal, the PET image was smoothed using
a 4-mm full width at half maximum (FWHM) Gaussian
filter to compensate for potential inaccuracies in the co-
registration. Individual surfaces were registered to the
cortical surface of an average non-linear anatomical tem-
plate in the MNI space using a feature-driven surface
registration algorithm [25, 26]. Parameter values were
then mapped to the average surface and smoothed using
a 20-mm FWHM geodesic Gaussian kernel. Smoothing
along the cortical surface eliminates unwanted blurring
across gyri caused by smoothing in voxel space.
Cortical thickness was determined by estimating the
distance between the white matter (WM)-GM surface
and the GM-CSF surface at each location of the cortical
surface, producing a cortical thickness surface map for
each individual. Using the same approach as before, in-
dividual cortical thickness maps were mapped to the
average surface and smoothed.
Statistical analyses
Correlation between parameters was calculated at each
point/vertex on the cortical surface using a linear regres-
sion model implemented in Python 3.7.3 (Python
Software Foundation). This produced a statistical map of
the cortical surface with each vertex indicating regres-
sion slopes different from zero. Vertices with positive t-
values indicate positive correlations and vice versa. In
order to adjust for multiple comparisons, results from
both positive and negative correlations were family-wise
error rate (FWER) corrected using cluster-extent-based
thresholding with varying primary cluster-defining
thresholds for significance of p < 0.01 and p < 0.001 (both
shown as overlay in figures). We chose to show thresh-
olds of p < 0.01 and p < 0.001 as our primary findings. In
Additional files 1, 2, 3, and 4, we have added the more
lenient threshold of p < 0.05 to better comprehend the
patterns of correlations. The cluster-extent threshold for
significance was calculated using a Gaussian random
field implemented in Statistical Parametric Mapping 12
(SPM12; Wellcome Trust Centre for Neuroimaging) tak-
ing into account the estimated intrinsic smoothness
based in residual maps [27]. Visbrain was used for
visualisation of the surface-based statistical maps [28].
Spearman’s Rho (ρ) was applied to test for correlation
between NfL–MMSE and NfL–CDR sum-of-boxes
(CDR-SOB).
Results
Twenty-seven MCI/AD subjects (8 females/19 males)
were included in the analyses. The subjects had a mean
age of 73.6 years (± 6.1), mean MMSE score of 25.9 (±
3.0), and a mean plasma NfL level of 27.9 pg/mL (±
10.7). One AD subject had no DWI sequence due to
claustrophobia, so MD analyses only include 26 subjects.
Plasma NfL correlated inversely with PK11195 BPND
levels in areas of frontal, parietal, precuneus, occipital,
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and sensorimotor cortices in the 27 MCI/AD cases
(Fig. 1). MD correlated positively with plasma NfL levels
in areas of the temporal lobes and the cingulate cortex
(Fig. 2a). Levels of MD correlated inversely with
PK11195 BPND primarily in parietal areas (Fig. 2b) and
overlapped with areas of PK11195–NfL inverse correl-
ation. It should be noted that not all subjects had whole-
brain coverage for the DWI sequence, which led to lack
of statistical inference in the most superior and inferior
parts of the cerebrum (shown as dark grey areas on the
figures involving MD). Finally, cortical thickness
correlated inversely with plasma NfL levels in a single
cluster in the left frontal lobe (Fig. 2c). There were no
correlations between cortical thickness and PK11195
binding. Additionally, no correlations were detected be-
tween MMSE ratings and plasma NfL levels (ρ = − 0.057,
P = 0.78) or cortical PK11195 binding, or between CDR-
SOB scores and plasma NfL levels (ρ = 0.257, P = 0.20)
or PK11195 binding.
Discussion
This paper is the first to report in vivo an inverse associ-
ation of plasma NfL concentrations with levels of cor-
tical microglial activation imaged with PET in patients
with prodromal or early mild AD confirmed by the pres-
ence of raised cortical β-amyloid deposition detected
with 11C-PiB PET. Since plasma NfL levels are now a
well-established biomarker for the extent of axonal
damage, these results suggest that cortical microglial ac-
tivation in early Aβ-positive individuals may initially play
a protective role.
Plasma NfL levels have been shown to correlate
strongly with those in CSF [7]. A recent study by Ashton
et al. found that plasma NfL concentrations correlated
with both severity of post-mortem neurofibrillary tangle
pathology and nerve cell loss from neurodegeneration
[29]. We have previously found PK11195 binding to be
associated with amyloid load in prodromal AD [15]. In
that series, it was noted that amyloid-positive MCI/AD
subjects with absent or very low tau load still presented
with high PK11195 binding [21]. This finding empha-
sises that β-amyloid aggregation can trigger an inflam-
matory brain response in vivo independent and ahead of
the presence of tau tangles.
Activated microglia can be seen surrounding amyloid
plaques and degenerating neurons containing tau tangles
in Alzheimer brain slices with immunohistochemical
stains [30]. The role of these microglia is still being de-
bated. It has been suggested that initially microglia may
be protective, attempting to clear toxic amyloid oligo-
mers in early disease and releasing nerve growth factors.
Subsequently, they fail to achieve this function and their
levels decline. A later wave of microglia is then activated
as tau tangles form and their load rises and these micro-
glia express a toxic phenotype releasing cytokines which
kill neurons and their axons so driving disease
Fig. 1 Correlations between 11C-PK11195 BPND and plasma NfL. Surface-based cortical statistics displaying negative correlations between
11C-
PK11195 BPND and plasma NfL levels in frontal, parietal, precuneus, occipital, and sensorimotor areas across 27 prodromal and early AD cases. The
presented maps are cluster-level FWER corrected at p < 0.05, with two different cluster-defining primary thresholds: p < 0.01 and p < 0.001
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progression [17]. PK11195 PET is unable to discriminate
between protective and cytotoxic activated microglia as
both these microglial phenotypes express TSPO. If the
majority of activated microglia in our MCI and early AD
cohort exhibit a protective phenotype, then this could
explain our observation of an inverse correlation be-
tween cortical microglial load and plasma NfL levels.
Surface-based cortical statistics showed that areas
where brain inflammation levels correlated with
plasma NfL levels in our MCI/AD group were local-
ised in frontal, cingulate, parietal, precuneus, occipital,
and sensorimotor cortices. The first four areas are
particularly targeted by amyloid deposition [31], while
occipital and primary sensorimotor cortices usually
are relatively spared. Pyramidal cells in layers 3 and 5
of association cortical areas project to the brainstem
and spinal cord, and hence, it is most likely that de-
generation of these axons is responsible for the leak-
age of NfLs into the plasma.
We also found cortical areas where there was an inverse
correlation between MD and PK11195 binding. These
areas overlapped with areas of NfL–PK11195 inverse asso-
ciation, but were smaller in extent. As both NfL and MD
are considered surrogate markers of axon loss, this result
could corroborate a model of activated microglia in areas
of intact microstructure. MD correlated positively with
NfL in areas associated with early involvement in AD.
Specifically, the left medial temporal lobe, the right lateral
temporal lobe, and the cingulate cortex showed this asso-
ciation. These areas may represent a later disease stage
where microglia are no longer protective and neurodegen-
eration has started. We found only a few small areas of in-
verse correlation between plasma NfL levels and cortical
thickness. Cortical thickness is not sensitive to the initial
neurodegeneration on an individual basis, and with the
small sample size studied here; the statistical power is
probably insufficient to pick up strong correlations for
cortical thickness measurements.
While other studies have found association between
cognitive function, e.g. MMSE and NfL [32], we found
no associations between cognitive function (MMSE,
CDR-SOB) and neither plasma NfL levels or cortical
PK11195 binding. This could be due to our small sample
size and the fact that it consist of MCI/early AD cases.
Limitations
Our study was cross-sectional, so we are unable to delin-
eate the longitudinal relationship between plasma NfL and
Fig. 2 Surface based cortical statistics. a Areas with positive correlation between MD and levels of plasma NfL in temporal and cingulate regions.
b Areas with negative correlation between MD and 11C-PK11195 BPND in parietal, precuneus, and occipital regions. c Areas with negative
correlation between cortical thickness and NfL in frontal region. The presented maps are cluster-level FWER corrected at p < 0.05, with two
different cluster-defining primary thresholds: p < 0.01 and p < 0.001. Dark grey indicate areas not covered in all subjects by DWI
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brain inflammation in AD from these data. The current
study is single centre and based on a relatively small sam-
ple of early AD cases, so the results need to be confirmed
in a larger cohort. We chose to visualise cluster-defining
thresholds of p < 0.01 and p < 0.001. In other imaging mo-
dalities, a threshold of p < 0.01 is considered too lenient
[33]; however, this has not been tested for PET and diffu-
sion MR imaging. Compared to newer TSPO tracers now
available, PK11195 PET has a low signal-to-noise ratio
due to a high background signal. In favour of PK11195
PET, however, is the finding that the signals are not sig-
nificantly influenced by the TSPO polymorphism
expressed by subjects unlike newer PET TSPO markers;
this simplifies the interpretation of imaging findings.
Conclusion
We have found that in early and prodromal Alzheimer pa-
tients raised plasma levels of NfL protein, a marker of axonal
neurodegeneration, are inversely correlated with raised levels
of PK11195 binding, a marker of microglial activation / neu-
roinflammation, in cortical areas. As raised plasma NfL re-
flect active neurodegeneration, our finding supports the
view that inflammation initially plays a protective role in
AD. Both these modalities have the potential to provide use-
ful biomarkers in future studies on the efficacy of neuropro-
tective agents. The inverse correlation of levels of raised
activated microglia in early AD with reduced plasma levels
of NfL could suggest that initially boosting microglia activa-
tion, possibly with immunotherapy targeting abnormal pro-
tein aggregations, in early disease could be protective, but
this hypothesis needs to be tested in further studies.
Additional files
Additional file 1: Figure S1. Correlations between 11C-PK11195 BPND
and plasma NfL levels at three different cluster defining thresholds: p <
0.05, p < 0.01, p < 0.001. All are cluster-level FWER corrected at p < 0.05. In-
cluding scatter plot of subject mean values of the largest cluster surviving
p < 0.05 FWER correction with a primary cluster defining threshold of p <
0.01 (indicated by black arrow).
Additional file 2: Figure S2. Correlations between MD and plasma NfL
levels at three different cluster defining thresholds: p < 0.05, p < 0.01, p <
0.001. All are cluster-level FWER corrected at p < 0.05. Including scatter plot
of subject mean values of the largest cluster surviving p < 0.05 FWER correc-
tion with a primary cluster defining threshold of p < 0.01 (indicated by black
arrow). Dark grey indicate areas not covered in all subjects by DWI.
Additional file 3: Figure S3. Correlations between 11C-PK11195 BPND
and MD at three different cluster defining thresholds: p < 0.05, p < 0.01, p <
0.001. All are cluster-level FWER corrected at p < 0.05. Including scatter plot
of subject mean values of the largest cluster surviving p < 0.05 FWER correc-
tion with a primary cluster defining threshold of p < 0.01 (indicated by black
arrow). Dark grey indicate areas not covered in all subjects by DWI.
Additional file 4: Figure S4. Correlations between cortical thickness
and plasma NfL levels at three different cluster defining thresholds: p <
0.05, p < 0.01, p < 0.001. All are cluster-level FWER corrected at p < 0.05. In-
cluding scatter plot of subject mean values of the largest cluster surviving
p < 0.05 FWER correction with a primary cluster defining threshold of p <
0.01 (indicated by black arrow).
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